Dexamethasone induces the expression of LRRK2 and α-synuclein, two genes that when mutated cause Parkinson's disease in an autosomal dominant manner

BMB Reports

Volumn 46, Issue 9, 2013, Pages 454-459

  Park, Ji Min ^a,c   Ho, Dong Hwan ^b   Yun, Hye Jin ^a   Kim, Hye Jung ^b   Lee, Chan Hong ^a   Park, Sung Woo ^a   Kim, Young Hoon ^a   Son, Ilhong ^b   Seol, Wongi ^a,b  

^a Inje University   (South Korea)

^b Wonkwang University   (South Korea)

^c CHA University   (South Korea)

Author keywords

Synuclein; Dexamethasone; Glucocorticoid receptor(GR); LRRK2; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL; ARTICLE; CELL LINE; CELL SURVIVAL; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; PARKINSON DISEASE; PATHOLOGY; PROMOTER REGION; TRANSCRIPTION INITIATION;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; CELL SURVIVAL; DEXAMETHASONE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; MICE; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTIONAL ACTIVATION;

EID: 84885453138     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2013.46.9.234     Document Type: Article

References (30)

1. Martin, I., Dawson, V. L. and Dawson, T. M. (2011) Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics. Hum. Genet. 12, 301-325.
2. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Marti-Masso, J. F., Perez-Tur, J., Wood, N. W. and Singleton, A. B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
3. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Carbajal, I. C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K. and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
4. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L. and Dawson, T. M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232.
5. Seol, W. (2010) Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep. 43, 233-244.
6. Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Schapira, A. H., Lynch, T., Bhatia, K. P., Gasser, T., Lees, A. J. and Wood, N. W. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a casecontrol study. Lancet. Neurol. 7, 583-590.
7. Smith, L. K., Jadavji, N. M., Colwell, K. L., Katrina Perehudoff, S. and Metz, G. A. (2008) Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur. J. Neurosci. 27, 2133-2146.
8. Heo, H. Y., Park, J. M., Kim, C. H., Han, B. S., Kim, K. S. and Seol, W. (2010) LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp. Cell Res. 316, 649-656.
9. Shin, N., Jeong, H., Kwon, J., Heo, H. Y., Kwon, J. J., Yun, H. J., Kim, C. H., Han, B. S., Tong, Y., Shen, J., Hatano, T., Hattori, N., Kim, K. S., Chang, S. and Seol, W. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314, 2055-2065.
10. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Miller, D., Blancato, J., Hardy, J. and Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
11. Franssens, V., Boelen, E., Anandhakumar, J., Vanhelmont, T., Buttner, S. and Winderickx, J. (2010) Yeast unfolds the road map toward alpha-synuclein-induced cell death. Cell Death. Differ. 17, 746-753.
12. Lopes da Silva, S. and Burbach, J. P. (1995) The nuclear hormone-receptor family in the brain: classics and orphans. Trends Neurosci. 18, 542-548.
13. Zetterstrom, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L. and Perlmann, T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250.
14. Kim, H. J., Fan, X., Gabbi, C., Yakimchuk, K., Parini, P., Warner, M. and Gustafsson, J. A. (2008) Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc. Natl. Acad. Sci. U. S. A. 105, 2094-2099.
15. Sarkanen, J. R., Nykky, J., Siikanen, J., Selinummi, J., Ylikomi, T. and Jalonen, T. O. (2007) Cholesterol supports the retinoic acid-induced synaptic vesicle formation in differentiating human SH-SY5Y neuroblastoma cells. J. Neurochem. 102, 1941-1952.
16. Valente, V., Teixeira, S. A., Neder, L., Okamoto, O. K., Oba-Shinjo, S. M., Marie, S. K., Scrideli, C. A., Paco-Larson, M. L. and Carlotti, C. G., Jr. (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol. Biol. 10, 17.
17. Farrer, M., Wavrant-De Vrieze, F., Crook, R., Boles, L., Perez-Tur, J., Hardy, J., Johnson, W. G., Steele, J., Maraganore, D., Gwinn, K. and Lynch, T. (1998) Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann. Neurol. 43, 394-397.
18. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D. and Langston, J. W. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174-179.
19. Gibberd, F. B. and Simmonds, J. P. (1980) Neurological disease in ex-Far-East prisoners of war. Lancet 2, 135-137.
20. Charlett, A., Dobbs, R. J., Purkiss, A. G., Wright, D. J., Peterson, D. W., Weller, C. and Dobbs, S. M. (1998) Cortisol is higher in parkinsonism and associated with gait deficit. Acta. Neurol. Scand. 97, 77-85.
21. Smith, A. D., Castro, S. L. and Zigmond, M. J. (2002) Stress-induced Parkinson's disease: a working hypothesis. Physiol. Behav. 77, 527-531.
22. Muller, T., Welnic, J. and Muhlack, S. (2007) Acute levodopa administration reduces cortisol release in patients with Parkinson's disease. J. Neural. Transm. 114, 347-350.
23. Muller, T. and Muhlack, S. (2007) Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. Clin. Neuropharmacol. 30, 101-106.
24. Lutzner, N., Kalbacher, H., Krones-Herzig, A. and Rosl, F. (2012) FOXO3 is a glucocorticoid receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a positive autoregulatory loop. PLoS One 7, e42166.
25. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. and Lansbury,Jr. P.T. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
26. Saito, H., Koyasu, J., Shigeoka, T. and Tomita, I. (1994) Cytotoxicity of chlorophenols to goldfish GFS cells with the MTT and LDH assays. Toxicol. In Vitro 8, 1107-1112.
27. Dai, Y. B., Tan, X. J., Wu, W. F., Warner, M. and Gustafsson, J. A. (2012) Liver X receptor beta protects dopaminergic neurons in a mouse model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 109, 13112-13117.
28. Cho, S. J., Lee, H., Dutta, S., Seog, D. H. and Moon, I. S. (2012) Translation elongation factor-1A1 (eEF1A1) localizes to the spine by domain III. BMB Rep. 45, 227-232.
29. Bauer, M., Kinkl, N., Meixner, A., Kremmer, E., Riemenschneider, M., Forstl, H., Gasser, T. and Ueffing, M. (2009) Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene. Ther. 16, 142-147.
30. Kwon, H. S., Park, J. A., Kim, J. H. and You, J. C. (2012) Identification of anti-HIV and anti-reverse transcriptase activity from Tetracera scandens. BMB Rep. 45, 165-170.